Synopsis: The AUSTRi trial evaluated the safety of combination fluticisone-salmeterol in moderate to severe asthma, and this medication was found to be noninferior to fluticasone alone. This is an important first study in validating the use of this medication in asthmatic patients after earlier controversial studies suggested the risk of routinely adding long-acting β-agonists to the management of asthma patients.
Source: Stempel, DA, Raphiou IH, Kral KM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med. 2016;374(19):1822–1830.
Disclosure: The authors declare that they have no conflicts of interest.